Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Czech steam-turbine manufacturer Doosan Skoda Power AS launched an initial public offering, touting an outlook for high ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

Pete Giacchi, Citadel Securities, joins 'Money Movers' to discuss Venture Global's initial public offering, the biggest IPO ...

Venture Global's IPO represents a test for investor appetite for fossil fuel projects in the Trump administration.

The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Snag is, Cheniere’s two export terminals are already advanced enough to generate several billion dollars in cash flow, much of which is already flowing in dividends to shareholders. Venture Global is ...

More generally, markets have a way of recalibrating, and Venture Global’s IPO offers a nuanced lesson. It’s a reminder that valuations aren’t fixed by management or banker decree, but rather hammered ...

Pine Labs is reportedly gearing up to file its draft papers for an initial public offering by the middle of next month.